Monocyte Chemoattractant Protein-1 and Menopause Hormone Therapy′s Cardiovascular Protective Effect
LIU Wen-hua
TANG Shan-shan
DENG Miao
ZHANG Hong-yan
ZHANG Zhi-fen
Abstract：A variety of diseases, including cardiovascular disease, are widely recognized as inflammatory diseases. Many cytokines and chemokines are involved in the pathological processes of cardiovascular disease. Menopause is estrogen′s deficiency, which leads to the glucolipid metabolic abnormality, inflammatory factors′ imbalance, the state of chronic inflammation. Monocyte chemoattractant protein-1 (MCP-1) induces and regulates the formation and release of other inflammatory cytokines, mediating inflammation, therefore is considered as the start of the inflammatory factor. MCP-1 chemokines monocyte from the lumen to the subendothelial space, initiating foam cells and fatty streak formation that leads to atherosclerotic plaque formation, which is considered to be the key factor of atherosclerosis. Research has shown that menopause hormone therapy (MHT) can down regulate the level of postmenopausal women serum MCP-1,so as to exert its effect of cardiovascular protection. MCP-1 and the cardiovascular protective effect of MHT will be summarized.
Keywords：Monocyte chemoattractant proteinsReceptorsCCR2Cardiovascular diseasesMenopause hormone therapy
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 485-487,491 )